Back to search

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

Data up to Jan 2025

Published1999
Citations146
References23

Total Citations Per Year

Abstract

References (23)

Derivation of the sledai. A disease activity index for lupus patients

1992 • 4,410 citations

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

1989 • 792 citations

Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice.

1978 • 637 citations

Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

1983 • 453 citations

Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

1982 • 421 citations

Physiological importance of dehydroepiandrosterone

1994 • 367 citations

Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function.

1990 • 349 citations

Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells

1990 • 324 citations

Low plasma androgens in women with systemic lupus erythematosus

1987 • 286 citations

Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women

1997 • 285 citations

Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells

1991 • 275 citations

Sex hormone modulation of autoimmunity in NZB/NZW mice

1979 • 233 citations

Dehydroepiandrosterone in systemic lupus erythematosus

1995 • 201 citations

Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone.

1985 • 148 citations

Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

1998 • 129 citations

Low plasma androgens in women with active or quiescent systemic lupus erythematosus

1982 • 117 citations

Control of Adrenal Androgen Secretion

1991 • 109 citations

Estrogen, progesterone, and testosterone: Can they be used to treat autoimmune diseases?

1994 • 90 citations

Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE)

1995 • 87 citations

Corticosteroid-induced Osteoporosis

1990 • 67 citations

Therapeutic studies in new zealand mice

1980 • 67 citations

Natural Regulators of T-Cell Lymphokine Production In Vivo

1992 • 45 citations

Dehydroisoandrosterone prevention of autoimmune disease in NZB/W F1 mice: lack of an effect on associated immunological abnormalities

1989 • 21 citations

Cited By (0)

No citing papers found in database

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe… (1999) – Lupus | Metascience Observatory Explorer